# Peptic Ulcer Disease

Peptic ulcer disease requires prompt distinction of uncomplicated ulcer from hemorrhage, obstruction, or malignancy. Management centers on removing NSAID exposure when feasible, identifying and eradicating Helicobacter pylori, acid suppression, and timely endoscopic intervention for bleeding or concerning gastric ulcers.

**Clinical question:** How should physicians evaluate and manage peptic ulcer disease while addressing H. pylori, NSAID exposure, bleeding, obstruction, and gastric malignancy risk?

Updated: 2026-08-21T01:35:56.199138+00:00

## What matters in practice
- Gastritis is histologic mucosal inflammation; gastropathy denotes gastric lesions with minimal or no inflammation, an important distinction when interpreting endoscopic and pathology findings. [1]
- The major reversible causes of gastric ulcer are H. pylori infection and NSAID exposure; stopping the NSAID is associated with healing in 95% of NSAID-associated ulcers. [3][12]
- For a gastric ulcer, obtain H. pylori testing by rapid urease testing plus ulcer biopsies; if testing is negative while the patient is taking a PPI or has used antibiotics within the prior month, use stool antigen testing after a 2-week PPI washout. [3]
- High-risk bleeding peptic ulcers require endoscopic hemostatic therapy; endoscopy is also indicated for hemorrhage and possible gastric outlet obstruction. [17][19]
- Describe ulcer size and location, document with white-light and virtual chromoendoscopic photographs, and recognize irregular borders, elevated edges, contact bleeding, fold disruption, a discolored base, large size, and non-antral location as malignant features. [3]

## Identify complications and the actionable cause

The immediate decision is whether the patient has bleeding, obstruction, perforation, or a lesion concerning for malignancy.

Peptic ulcer disease is most often linked to H. pylori infection or NSAID exposure. Establish medication exposure, including ongoing NSAID and antiplatelet use, and assess for overt or occult upper gastrointestinal bleeding, vomiting or retained gastric contents suggesting outlet obstruction, and features requiring urgent endoscopic assessment. [3][15][17]

Gastric ulcers deserve particular attention because some endoscopic appearances raise concern for malignancy. Potentially malignant features include a large solitary ulcer, non-antral location, a discolored or necrotic-appearing base, elevated or irregular borders, raised edges with contact bleeding, and disrupted gastric folds. In contrast, nonmalignant ulcers more often are smaller, antral, sharply marginated, and surrounded by normal mucosa. [3]
- Document ulcer size and location at endoscopy. [3]
- Photograph gastric ulcers with white light and virtual chromoendoscopy; near-focus or magnification assessment is also recommended in the cited endoscopy guidance. [3]
- Treat upper gastrointestinal hemorrhage or suspected outlet obstruction as an endoscopic indication rather than an outpatient dyspepsia-management problem. [17]

*Endoscopic findings that should change diagnostic concern and next steps. [3]*

| Finding | Clinical implication |
| --- | --- |
| Large solitary, non-antral gastric ulcer | Potential malignant characteristic; carefully characterize and biopsy the ulcer. [3] |
| Discolored base, elevated or irregular border | Potential malignant characteristic; assess with high-quality imaging and tissue sampling. [3] |
| Raised edge with contact bleeding or gastric fold disruption | Additional concerning features for malignant ulcer. [3] |
| Smaller antral ulcer with well-defined margins and normal surrounding mucosa | More typical of a nonmalignant ulcer appearance, but does not replace appropriate diagnostic evaluation. [3] |

## Test for active H. pylori infection and verify eradication when indicated

Testing must account for false-negative results from acid suppression and recent antibiotic exposure.

In gastric ulcer, the cited upper-endoscopy guidance recommends rapid urease testing and biopsies of the ulcer for H. pylori. If both urease testing and histology are negative in a patient receiving a PPI or exposed to antibiotics within the preceding month, obtain a stool antigen test after the procedure once the patient has been off PPI therapy for 2 weeks. [3]

Urea breath testing and stool antigen testing identify active infection. A 2-week washout after PPI or antibiotic use is described for these tests in the supplied primary-care guidance, although its statement groups these agents and does not provide a U.S. specialty-society testing protocol. [22][24]

Provide eradication therapy for a positive rapid urease test or stool antigen test. The supplied evidence identifies bismuth-containing quadruple therapy as a commonly used empiric approach internationally, generally for 10 or 14 days, but does not provide enough source-supported drug doses or a U.S. regimen-selection algorithm for this article. [3][11]
- Do not use serology to establish active infection or confirm cure when an active-infection test is available; urea breath and stool antigen tests detect active infection. [24]
- In the setting of bleeding peptic ulcer, interpret rapid urease testing cautiously; the supplied study notes concerns about CLO-test reliability, whereas histology was comparatively consistent. [24]
- A supplied primary-care guide recommends retesting 6 to 8 weeks after treatment begins, but the excerpt does not establish the preferred U.S. timing or modality for test of cure. [22]

*H. pylori testing considerations in peptic ulcer disease. [3][22][24]*

| Clinical setting | Supported testing approach | Interpretive issue |
| --- | --- | --- |
| Gastric ulcer at index endoscopy | Rapid urease test plus ulcer biopsies. [3] | Use both modalities as recommended in the cited endoscopy guidance. [3] |
| Negative urease test and histology with PPI use or antibiotics in prior month | Stool antigen testing after the procedure and after 2 weeks off PPI therapy. [3] | Recent PPI or antibiotic exposure may contribute to a false-negative initial evaluation. [3] |
| Need to establish active infection noninvasively | Urea breath test or stool antigen test. [22][24] | Both detect active infection; no single test is definitive in all circumstances. [24] |
| Bleeding ulcer | Include histology in the assessment. [24] | Rapid urease testing may be less reliable according to the supplied study. [24] |

## Remove ulcerogenic exposure and use acid suppression strategically

Cause-directed therapy is central; acid suppression supports healing and is integral to bleeding-ulcer management.

For an NSAID-associated ulcer, discontinue the NSAID when clinically feasible. A recent JAMA review reports ulcer healing in 95% of cases after stopping the causative NSAID. [12]

The supplied literature supports PPI treatment in ulcer care and indicates that low-dose aspirin does not appear to delay peptic-ulcer healing when treated with a PPI. The cited evidence involved aspirin 80 to 100 mg daily and should not be extrapolated to higher aspirin doses or other antithrombotic regimens without individualized assessment. [4]

Misoprostol 200 mcg four times daily is reported as approved for prevention of NSAID-induced gastric and duodenal ulcers; diarrhea is a clinically important adverse effect. The supplied excerpt does not provide sufficient current evidence to specify comparative selection, contraindications, or contemporary U.S. dosing recommendations for PPIs, H2-receptor antagonists, or eradication regimens. [9]
- If aspirin is being used for cardiovascular protection, balance thrombotic risk against recurrent bleeding risk rather than assuming aspirin must be withheld until ulcer healing; cited evidence supports PPI-treated healing with low-dose aspirin. [4]
- Do not rely on stopping an NSAID alone when H. pylori is detected; provide eradication therapy for positive testing. [3]
- Avoid unsupported antibiotic empiricism: resistance and ineffective treatment are recognized concerns in H. pylori management. [14]

*Cause-directed medical actions supported by the supplied sources. [3][4][9][12]*

| Clinical driver | Action | Key limitation or tradeoff |
| --- | --- | --- |
| NSAID-associated ulcer | Stop the NSAID when feasible. [12] | Healing after stopping the NSAID was reported in 95% of cases. [12] |
| Positive H. pylori test | Provide eradication therapy. [3] | The supplied sources do not support a complete current U.S. regimen and dosing specification. [3][11] |
| Low-dose aspirin needed for cardiovascular protection | Use PPI-treated ulcer management while weighing thrombotic and hemorrhagic risks. [4] | Cited healing evidence used aspirin 80 to 100 mg daily. [4] |
| Need to prevent NSAID-induced ulcer | Misoprostol 200 mcg four times daily is described as approved for prevention. [9] | Diarrhea may limit tolerability. [9] |

## Treat high-risk ulcer bleeding endoscopically

Peptic ulcer disease remains the leading cause of nonvariceal upper gastrointestinal hemorrhage in the supplied review.

Peptic ulcer disease is described as the most common cause of upper gastrointestinal hemorrhage, ahead of gastritis and esophagitis. Endoscopy is indicated for hemorrhage, and endoscopic hemostatic therapy is identified as the treatment of choice for a high-risk bleeding peptic ulcer. [15][17][19]

The supplied evidence does not provide a complete current U.S. pre-endoscopic risk-stratification pathway, transfusion threshold, timing-to-endoscopy standard, endoscopic modality selection, post-endoscopic PPI dose, or rebleeding algorithm. These decisions should therefore be checked against current upper gastrointestinal bleeding guidance and individualized to hemodynamic status, lesion findings, comorbidity, and antithrombotic indication.
- Perform endoscopic evaluation for active or suspected ulcer hemorrhage. [17]
- Use endoscopic hemostasis for a high-risk bleeding ulcer. [19]
- For a gastric ulcer, include H. pylori assessment at endoscopy and provide eradication when testing is positive. [3]

*Supported management principles for bleeding peptic ulcer disease. [3][15][17][19]*

| Problem | Supported action |
| --- | --- |
| Upper gastrointestinal hemorrhage suspected to arise from peptic ulcer disease | Proceed to endoscopy for hemorrhage control and diagnosis. [17] |
| High-risk bleeding peptic ulcer at endoscopy | Use endoscopic hemostatic therapy. [19] |
| Gastric ulcer in the bleeding evaluation | Test for H. pylori with rapid urease testing and ulcer biopsies. [3] |

## Recognize and evaluate gastric outlet obstruction

Persistent vomiting and retained gastric contents require assessment for mechanical obstruction and alternative etiologies.

Endoscopy is indicated for possible gastric outlet obstruction in the setting of peptic ulcer disease. Distention with retained ingested contents and air may suggest a component of outlet obstruction or gastroparesis, but this finding is not specific for an ulcer-related mechanical obstruction. [8][17]

If obstruction is present, distinguish benign ulcer-related narrowing from malignancy, especially when a gastric lesion has irregular, elevated, discolored, non-antral, or otherwise concerning features. The supplied evidence does not provide a contemporary, source-supported U.S. algorithm for dilation, stenting, surgery, or nutritional rescue in ulcer-related obstruction. [3]
- Use endoscopy when symptoms or imaging suggest gastric outlet obstruction. [17]
- Assess for malignant ulcer features before attributing obstruction solely to benign peptic disease. [3]
- Escalate to surgical management when hemorrhage cannot be controlled endoscopically; this principle is stated in the supplied source, although no procedural threshold is provided. [17]

*Findings relevant to suspected ulcer-related gastric outlet obstruction. [3][8][17]*

| Finding | Clinical implication |
| --- | --- |
| Vomiting with retained gastric contents or gastric distention | Consider gastric outlet obstruction, while retaining gastroparesis in the differential. [8] |
| Possible obstruction in peptic ulcer disease | Endoscopy is indicated for evaluation. [17] |
| Obstruction plus concerning gastric-ulcer morphology | Prioritize evaluation for malignancy. [3] |

## Common questions

### How should H. pylori be tested in a patient with a gastric ulcer?

At endoscopy, obtain rapid urease testing and ulcer biopsies. If both are negative but the patient is taking a PPI or used antibiotics within the prior month, obtain stool antigen testing after 2 weeks off PPI therapy. [3]

### Should an NSAID be continued after an NSAID-associated peptic ulcer?

Stop the NSAID when feasible. A recent review reports healing in 95% of NSAID-associated ulcers after discontinuation; if antiplatelet therapy is necessary, individualize thrombotic versus bleeding risk. [4][12]

### Which gastric ulcer appearances are concerning for malignancy?

Concerning features include a large solitary or non-antral ulcer, discolored base, elevated or irregular border, raised edge with contact bleeding, and disrupted gastric folds. [3]

### What is the definitive therapy for a high-risk bleeding peptic ulcer?

Endoscopic hemostatic therapy is the treatment of choice for high-risk bleeding peptic ulcers. [19]

### When should suspected peptic-ulcer gastric outlet obstruction undergo endoscopy?

Endoscopy is indicated for possible gastric outlet obstruction. Retained gastric contents and distention can support the suspicion but may also reflect gastroparesis. [8][17]

## References
1. Gastritis - Symptoms, diagnosis and treatment | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/816
2. British Society of Gastroenterology guidelines on ... — gut.bmj.com — https://gut.bmj.com/content/74/Suppl_2/s1
3. British Society of Gastroenterology and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland guidance on best practice for upper gastrointestinal endoscopy | Frontline Gastroenterology — fg.bmj.com — https://fg.bmj.com/content/early/2026/04/28/flgastro-2025-103455
4. Asia-Pacific working group consensus on non-variceal ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/67/10/1757.full.pdf
5. A Controlled Study of Ranitidine for the Prevention ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJM199402103300602
6. Prevention and management of major complications in percutaneous endoscopic gastrostomy | BMJ Open Gastroenterology — bmjopengastro.bmj.com — https://bmjopengastro.bmj.com/content/8/1/e000628
7. Gastric outlet obstruction due to pyloric mass in a 12-year- ... — adc.bmj.com — https://adc.bmj.com/content/104/3/302
8. Large gastric ulcer presenting as gastric pneumatosis — casereports.bmj.com — https://casereports.bmj.com/content/16/9/e256724
9. Medical Treatment of Peptic Ulcer Disease — jamanetwork.com — https://jamanetwork.com/journals/jama/articlepdf/397278/jama_275_8_033.pdf?resultClick=1
10. The sequential therapy regimen for Helicobacter pylori eradication — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2007/06/13/gut.2007.125658.full.pdf
11. Based Helicobacter pylori Infection Control and Management (2021 ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/71/2/238.full.pdf
12. Peptic Ulcer Disease | Gastroenterology — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2830296
13. Management of Nonvariceal Upper Gastrointestinal Bleeding — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/M19-1795
14. Treatment of H. pylori infection and gastric ulcer — www.cell.com — https://www.cell.com/heliyon/fulltext/S2405-8440(23)07614-4
15. An update on the management of non-variceal upper ... — academic.oup.com — https://academic.oup.com/gastro/article/doi/10.1093/gastro/goad011/7081277
16. Endoscopic hemostasis of a bleeding marginal ulcer: ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1046/j.1440-1746.2002.02875.x
17. Acid Peptic Disorders — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781118572610.ch21
18. Peptic Ulcer Diseases: Genetics, Mechanism, and Therapies — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2014/898349
19. Effect of High‐Dose Oral Rabeprazole on Recurrent ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1155/2012/317125
20. Study Details | NCT02959255 | 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT02959255
21. Appendix D: Evidence Tables [update 2014] - D.1 Question 1 — www.nice.org.uk — https://www.nice.org.uk/guidance/cg184/evidence/appendix-d-q1q4-evidence-tables-pdf-193203761
22. PHC ENG GUIDE 200 - Extranet Systems — extranet.who.int — https://extranet.who.int/ncdccs/Data/LBN_D1_Final%20EN%20PHC%20Guide%20(September%2025,%202015).pdf
23. Appendix G: Excluded studies - G.1 Question 1 — www.nice.org.uk — https://www.nice.org.uk/guidance/cg184/evidence/appendix-g-excluded-studies-pdf-193203765
24. Low recovery rate of helicobacter pylori from positive CLO ... — applications.emro.who.int — https://applications.emro.who.int/imemrf/Bahrain_Med_Bull/Bahrain_Med_Bull_2015_37_2_117_120.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.